Sisram Medical's China Manufacturing Facility Commences Operations as First Locally Produced Alma Rejuve Rolls Off the Line

About this update from Sisram Medical Ltd.

Localization strategy advances with strengthened end-to-end capabilities across R&D, manufacturing and commercialization HONG KONG, June 28, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced that its China manufacturing facility in Miyun, Beijing has commenced operations, with the first locally produced EBD, Alma Rejuve, rolling off the production line. The facility underpins the Company's revamped global smart manufacturing network, bringing its proven Israeli production standards to China to drive iterative local production upgrades, marking a pivotal milestone as Sisram's China localization strategy moves into full commercial operation. The Beijing facility was jointly established by Sisram Medical (Tianjin) Ltd., a wholly-owned subsidiary of the Company, and Sinmait Medical Technology (Beijing) Co., Ltd. The facility adopts the Israeli manufacturing arm's field-validated production workflows, stringent QC protocols and decades of R&D and manufacturing expertise. Its state-of-the-art lines build on this foundation to deliver iterative upgrades to the Company's full manufacturing capabilities. Leveraging Fosun Pharma's robust manufacturing ecosystem and premium domestic supply chain, the facility is expected to expand Sisram's localized production portfolio while improving supply efficiency, delivery responsiveness, product quality consistency and after-sales service capabilities. Alma Rejuve, recognized in China for its anti-aging and skin rejuvenation applications, has become a trusted choice among clinics and consumers. Its local production will further enhance product availability and strengthen Sisram's market reach. The commencement of operations at the Beijing facility, together with the successful rollout of the first Alma Rejuve, represents a significant milestone in the continued advancement of Sisram's localization strategy in China. Through localized intelligent manufacturing, the Company is enhancing operational efficiency and market responsiveness, while strengthening integration across R&D, manufacturing, sales and after-sales support. This more integrated operating model will help establish a full industry chain that anchors the Company's long-term growth in China. Over the l...

View stock analysis, news, and events for Sisram Medical Ltd.